Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary ...

Sales were “overall below the most conservative buyside expectations,” Citi analysts said, with wines and spirits suffering ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

The data "are pretty much a best-case scenario, in our view - on weight loss, blood sugar control, tolerability, safety," BofA Securities ... along with Denmark's Novo Nordisk (NVO) (DK:NOVO.B ...

It was overtaken by Danish drugmaker Novo Nordisk in late 2023 — before ... as fundamentals will likely remain tough in the short term," Bank of America Global Research analysts said in a ...

BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster ...

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...